CHOSA Oncology reduced its Q2 loss year-over-year, strengthened its cash position, and advanced its cisplatin-DRP and LiPlaCis programs, supported by a recent share issue and growing industry recognition.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.